# Trial in Patients With Relapsed Ovarian Cancer

> **NCT03267589** · PHASE2 · COMPLETED · sponsor: **Nordic Society of Gynaecological Oncology - Clinical Trials Unit** · enrollment: 25 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562

## Key facts

- **NCT ID:** NCT03267589
- **Lead sponsor:** Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-14
- **Primary completion:** 2021-10-19
- **Final completion:** 2021-10-19
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267589, "Trial in Patients With Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03267589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*